Sexual Health

Know and Calibrate your Sexual Life

Advertisement

Breast Cancer: Everything there is to know about.

Breast Cancer
Breast Cancer
Designed by Freepik

Breast cancer is a type of cancer that originates in the cells of the breast tissue, typically in the ducts (which carry milk to the nipple) or lobules (glands that produce milk). It’s one of the most common cancers affecting women worldwide, although men can also develop it, albeit rarely. Over the years, advancements in screening, diagnostics, and treatment have significantly improved the outcomes for breast cancer patients.

Symptoms of Breast Cancer

The symptoms of breast cancer can vary, but common signs to watch for include:

  • Lump in the breast or armpit – Often the first noticeable symptom; it may feel hard, irregular, and painless.
  • Changes in breast shape or size – One breast may appear larger or its shape altered.
  • Nipple discharge – This could be clear, milky, or blood-tinged.
  • Dimpling or thickening of breast skin – Skin may take on an “orange-peel” texture or appear red and swollen.
  • Nipple inversion – The nipple may turn inward or flatten.
  • Persistent pain in the breast – Especially if localized and non-cyclic.

Causes of Breast Cancer

Breast cancer is multifactorial, meaning its development is influenced by various genetic, environmental, and lifestyle factors:

  • Genetic mutations – BRCA1 and BRCA2 gene mutations are associated with a higher risk.
  • Family history – Having a close relative with breast cancer increases risk.
  • Hormonal factors – Long-term exposure to estrogen, due to factors like late menopause or early menstruation, can raise risk.
  • Lifestyle factors – Obesity, alcohol use, and lack of physical activity contribute.
  • Radiation exposure – Especially at a young age, can elevate the risk.
  • Reproductive history – Having children later in life or not breastfeeding may also play a role.

Treatment Options for Breast Cancer

  • Surgery – This includes lumpectomy (removing the tumor) or mastectomy (removal of the breast).
  • Radiation Therapy – Targets cancer cells in the breast and surrounding areas to reduce recurrence.
  • Chemotherapy – Involves drugs to kill cancer cells or stop them from growing, often used in advanced cases.
  • Hormone Therapy – Medications block hormones, like estrogen, which fuel certain types of breast cancer (e.g., tamoxifen).
  • Targeted Therapy – Uses drugs that target specific markers on cancer cells (e.g., HER2-positive cancers).
  • Immunotherapy – Boosts the immune system’s ability to fight cancer cells and is currently more experimental in breast cancer.

Latest Studies and Developments

  • Genomic Profiling for Personalized Treatment: Recent studies focus on using genomic profiling to tailor treatments based on individual genetic profiles. This approach, sometimes called “precision medicine,” aims to minimize side effects and improve efficacy.
  • AI for Early Detection: Research into AI-based tools has shown promising results in improving early detection accuracy by identifying tumors that are sometimes missed in traditional mammography.
  • Metastatic Breast Cancer Treatments: New drugs targeting metastatic breast cancer are showing promising results, such as those that inhibit proteins aiding in cancer spread or drugs like sacituzumab govitecan.
  • Vaccines in Trials: Experimental vaccines for breast cancer, particularly for triple-negative breast cancer, are under clinical trials. These vaccines aim to trigger an immune response specifically against cancer cells.
  • Hormone-Receptor Positive Treatment Advances: Studies on CDK4/6 inhibitors like palbociclib, often used alongside hormone therapy, have improved survival rates in hormone-receptor-positive breast cancer.

Some recent studies and researches about Breast Cancer

Recent studies have made important strides in breast cancer research, bringing forward new treatment approaches and improving outcomes for patients. In 2023, the NATALEE trial highlighted the efficacy of ribociclib, a CDK4/6 inhibitor, for hormone receptor-positive, HER2-negative early breast cancer. Results showed this combination with endocrine therapy (ET) extended invasive disease-free survival compared to ET alone. If confirmed by long-term results, this could offer a crucial tool for those with early-stage disease to reduce recurrence risk, a priority given that about 90% of breast cancer cases fall into this category.

Another important development is the expanded use of abemaciclib in node-positive, high-risk patients with HR+/HER2- cancer. Based on findings from the monarchE trial, abemaciclib, combined with ET, significantly improved recurrence-free rates compared to ET alone. This broadened indication, recently approved by the FDA, excludes the previous requirement for a high Ki-67 score, making the treatment accessible to more patients.

For advanced cases, the DESTINY-Breast02 trial studied trastuzumab deruxtecan (T-DXd) and demonstrated its effectiveness for patients with HER2-positive metastatic breast cancer previously resistant to trastuzumab emtansine. T-DXd extended treatment durations significantly compared to the treatment of physician’s choice (TPC), with a notable improvement in quality of life (QoL) scores, thanks to fewer side effects and a reduction in symptoms like nausea and vomiting. This adds a powerful option for patients with limited previous treatment success.

Moreover, the EMERALD trial explored elacestrant, a selective estrogen receptor degrader, in patients with ER-positive/HER2-negative advanced breast cancer. Its performance matched that of standard care in terms of progression-free survival and quality of life, but with reduced severe gastrointestinal side effects. This establishes elacestrant as a beneficial follow-up treatment, especially for those developing endocrine resistance, a common challenge in advanced cases.

Innovative studies have also explored non-pharmacological interventions like those in the LEANer study, which found that diet and exercise interventions significantly improved the pathological complete response (pCR) rate in patients undergoing chemotherapy for triple-negative or HR+/HER2- breast cancer. Not only did these lifestyle changes enhance response to treatment, but patients in the intervention group also reported better physical activity levels and dietary quality, illustrating the potential of lifestyle adjustments to augment medical treatments.

These advances in drug therapies and supportive care highlight the momentum in breast cancer research toward more personalized, effective, and less toxic treatments, with hopes for wider application pending further confirmation in long-term studies.

References:

Bing Search

Breast cancer now

AJMC

Daily Reporter

For Homepage click here

Leave a Reply

Your email address will not be published. Required fields are marked *